IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 381 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $862,410 | -69.3% | 21,019 | -73.3% | 0.00% | -75.0% |
| Q1 2023 | $2,809,843 | +2.0% | 78,619 | +7.8% | 0.00% | -20.0% |
| Q4 2022 | $2,753,433 | +2273.6% | 72,900 | +2233.5% | 0.01% | – |
| Q2 2022 | $116,000 | -67.4% | 3,124 | -67.5% | 0.00% | – |
| Q1 2022 | $356,000 | -79.8% | 9,611 | -83.4% | 0.00% | -100.0% |
| Q4 2021 | $1,763,000 | +6.7% | 57,924 | +57.6% | 0.00% | 0.0% |
| Q1 2021 | $1,653,000 | -31.5% | 36,762 | -13.9% | 0.00% | -50.0% |
| Q4 2020 | $2,414,000 | +146.6% | 42,687 | +107.0% | 0.00% | +100.0% |
| Q3 2020 | $979,000 | -88.2% | 20,625 | -85.3% | 0.00% | -88.9% |
| Q2 2020 | $8,268,000 | +88.1% | 140,226 | +50.9% | 0.02% | +50.0% |
| Q1 2020 | $4,395,000 | +21.9% | 92,951 | +55.7% | 0.01% | +71.4% |
| Q4 2019 | $3,605,000 | -57.9% | 59,680 | -58.2% | 0.01% | -61.1% |
| Q3 2019 | $8,562,000 | -66.5% | 142,921 | -64.1% | 0.02% | -65.4% |
| Q2 2019 | $25,558,000 | -18.9% | 397,664 | +2.4% | 0.05% | -14.8% |
| Q1 2019 | $31,515,000 | +41.3% | 388,255 | -5.9% | 0.06% | +22.0% |
| Q4 2018 | $22,298,000 | +10.3% | 412,500 | +5.3% | 0.05% | +35.1% |
| Q3 2018 | $20,209,000 | +50.8% | 391,800 | +21.8% | 0.04% | +42.3% |
| Q2 2018 | $13,405,000 | +12.9% | 321,700 | +19.5% | 0.03% | +30.0% |
| Q1 2018 | $11,871,000 | +62.6% | 269,300 | +85.6% | 0.02% | +42.9% |
| Q4 2017 | $7,299,000 | +21.3% | 145,100 | +22.2% | 0.01% | +16.7% |
| Q3 2017 | $6,018,000 | -20.1% | 118,700 | -19.8% | 0.01% | -29.4% |
| Q2 2017 | $7,529,000 | +68.1% | 148,000 | +32.8% | 0.02% | +41.7% |
| Q1 2017 | $4,479,000 | +45.0% | 111,410 | +72.4% | 0.01% | +9.1% |
| Q4 2016 | $3,090,000 | +64.4% | 64,610 | +25.9% | 0.01% | +57.1% |
| Q3 2016 | $1,880,000 | +115.1% | 51,310 | +36.8% | 0.01% | +75.0% |
| Q2 2016 | $874,000 | +61.0% | 37,510 | +179.9% | 0.00% | +100.0% |
| Q1 2016 | $543,000 | +4.4% | 13,400 | +59.6% | 0.00% | 0.0% |
| Q4 2015 | $520,000 | – | 8,396 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
| Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
| Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
| SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
| Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
| Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
| Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
| TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
| Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |